Coherus Oncology, Inc. - Common Stock (CHRS)

CUSIP: 19249H103

Q1 2020 13F Holders as of 31 Mar 2020

Holder snapshot 7 signals
Share change
+1,926,187
Put/Call ratio
84%
SEC-reported price per share
$16.22
Indexed holders
185
Value change
+$27,802,781
Number of buys
97
Open additional details 1 more signal available
Number of sells
88
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
154,050,897

Security key

19249H103

Report period

Q1 2020

Indexed institutions

185

Top holders

10

Ownership snapshot

Top reported holders of CHRS - Coherus Oncology, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Temasek Holdings (Private...
Disclosed value leader
Temasek Holdings (Private...
Comparable rows
0/15
Latest evidence
31 Dec 2019
13F Highest disclosed value: $132,897,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Temasek Holdings (Private) Ltd has the largest disclosed position value at $132.9M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Temasek Holdings (Private) Ltd's linked filing trail.
Disclosed position value Top 5
Temasek Holdings (Private) Ltd $132.9M
BlackRock Finance, Inc. $102.13M
STATE STREET CORP $62.77M
JPMORGAN CHASE & CO $62.25M
VANGUARD GROUP INC $55.43M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Temasek Holdings (Private) Ltd
13F
Company
13F
—
denominator unverified
$132,897,000
7,381,116 shares
— 31 Dec 2019
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$102,127,000
5,672,219 shares
— 31 Dec 2019
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$62,774,000
3,486,477 shares
— 31 Dec 2019
JPMORGAN CHASE & CO
13F
Company
13F
—
denominator unverified
$62,251,000
3,457,470 shares
— 31 Dec 2019
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$55,432,000
3,078,703 shares
— 31 Dec 2019
LORD, ABBETT & CO. LLC
13F
Company
13F
—
denominator unverified
$55,316,000
3,072,240 shares
— 31 Dec 2019
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2020

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
185
Shares
74,669,838
Indexed holders
185
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2020 vs Q4 2019 Across Filers

Q4 2019 indexed holders
184
Q1 2020 indexed holders
185
Indexed holder difference
1
Investor Q4 2019 Shares Q1 2020 Shares Share Diff Share Chg % Q4 2019 value Q1 2020 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .